Previous preclinical studies using CD27-based CAR construct demonstrated efficient anti-tumor response (15) and prolonged survival of CAR T cells in vivo by upregulating the anti-apoptotic protein Bcl-XL (16). This evidence concerns the gene BCL2L1 and neoplasm.